Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N.
Nishimoto N, et al. Among authors: kondo m.
Mod Rheumatol. 2014 Jan;24(1):17-25. doi: 10.3109/14397595.2013.854079.
Mod Rheumatol. 2014.
PMID: 24261754